Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of “Hold” by Analysts

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have earned an average rating of “Hold” from the nine research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $14.00.

Several research analysts recently issued reports on the company. Morgan Stanley dropped their price objective on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, April 10th. Oppenheimer dropped their price objective on Bicycle Therapeutics from $44.00 to $36.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 18th. Needham & Company LLC dropped their price objective on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Finally, Royal Bank Of Canada dropped their price objective on Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, March 18th.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC opened at $4.69 on Monday. Bicycle Therapeutics has a 52-week low of $4.24 and a 52-week high of $9.36. The stock has a market cap of $327.41 million, a P/E ratio of -1.49 and a beta of 1.54. The business’s 50 day moving average is $4.75 and its 200 day moving average is $5.79.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.25). Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%.The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $7.50 million. On average, sell-side analysts anticipate that Bicycle Therapeutics will post -1.98 EPS for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,967 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total transaction of $29,297.97. Following the sale, the chief executive officer owned 613,029 shares of the company’s stock, valued at approximately $3,009,972.39. This trade represents a 0.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 9,992 shares of company stock worth $49,363. 8.50% of the stock is currently owned by company insiders.

Institutional Trading of Bicycle Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Assetmark Inc. boosted its position in Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after acquiring an additional 1,552 shares in the last quarter. Man Group plc boosted its position in Bicycle Therapeutics by 4.8% during the 4th quarter. Man Group plc now owns 42,860 shares of the company’s stock valued at $303,000 after acquiring an additional 1,969 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Bicycle Therapeutics by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after acquiring an additional 2,243 shares in the last quarter. Flax Pond Capital LLC boosted its position in Bicycle Therapeutics by 1.4% during the 1st quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock valued at $817,000 after acquiring an additional 2,503 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in Bicycle Therapeutics by 21.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock valued at $116,000 after acquiring an additional 2,668 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.